← Back to screener

IRONWOOD PHARMACEUTICALS INC IRWD

Rank #1791 · Nasdaq · $0.6B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
42.1
P/E
654.7
P/B
-1.91
ROE
-0.3%
Op. Margin
26.5%
Debt Ratio
-216%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E 654.7x, P/B -1.91x. Ranks in the top 83% of the universe.

Profitability ★★★☆☆
Good

ROE -0.3%. Ranks in the top 40% of the universe.

Safety ★★★★★
Excellent

Debt ratio -216%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 14.4% year over year. Ranks in the top 88% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.1B$-0.1B$0.2B-177.289
2012$0.0B$-0.1B$-0.1B$0.1B-138.690
2013$0.1B$-0.1B–$0.2B-100.444
2014$0.2B$-0.1B–$0.1B-48.4154
2015$0.0B$-0.3B–$0.1B-1101.4129
2016$0.1B$-0.2B–$0.0B-221.61520
2017$0.1B$-0.1B$-0.1B$0.1B-68.3702
2018$0.3B$-0.1B$-0.1B$0.1B-18.9537
2019$0.3B$-0.0B$-0.1B$0.1B-5.2398
2020$0.3B$-0.2B$-0.3B$0.0B-43.53990
2021$0.4B$0.1B$0.0B$-0.2B28.0-385
2022$0.4B$0.1B$0.1B$0.6B36.786
2023$0.4B$0.2B$0.5B$0.7B56.169
2024$0.4B$0.3B$0.2B$-0.3B61.0-236
2025$0.4B$0.1B$0.0B$-0.3B26.5-216

← See the full screener